Sector News

BioMarin rises on buzz of a takeover–this time from Roche

July 11, 2016
Life sciences

BioMarin shares climbed more than 10% Thursday on talk of a potential takeover. And if that scenario sounds familiar, that’s because it is.

This time, the rumored interested buyer is Roche, according to the Betaville blog, whose sources say a deal for between $130 and $150 per share could be in the works. While it’s still unclear whether Roche has put forth a formal offer or held talks with BioMarin, one source said those processes may have been placed on hold on account of the Brexit vote and its impact on the markets.

It’s not the first time Betaville writer Ben Harrington has reported BioMarin interest from the Swiss pharma giant. Back in 2013, the blog said the Basel-based drugmaker was eyeing a $13.5 billion transaction for the San Rafael, CA-based company, fueling chatter that Roche CEO Severin Schwan tamped down not long thereafter.

For Roche, a cancer heavyweight, a buyout of BioMarin would beef up its rare-disease offerings, which currently include idiopathic pulmonary fibrosis med Esbriet. More recently, though, the buzzed-about potential buyer has been Sanofi, which Betaville said last month could be sizing up BioMarin as a potential backup if its quest to buy Medivation fails.

Lately, though, Sanofi’s taken a step in the right direction toward snagging its longtime target. Earlier this week, it agreed to drop a hostile pursuit of the California maker of prostate cancer star Xtandi after the company opened up its books.

Of course, it’s still entirely possible that Sanofi will lose out on its prize–especially considering that Medivation inked confidentiality pacts with “a number of parties” interested in a potential tie-up. Pfizer, AstraZeneca, Amgen , Gilead, Celgene and Novartis have all reportedly been taking a look at a deal for the San Francisco outfit.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 10, 2023

Brain waves found in sleep shown to protect against epileptic activity

Life sciences

Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.

December 10, 2023

Rousselot’s soft gel capsule stabilizing technology awarded USPTO patent

Life sciences

StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.

December 10, 2023

Roche to acquire obesity drug maker Carmot

Life sciences

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

How can we help you?

We're easy to reach